Showing 6,621 - 6,640 results of 27,596 for search '(( 5 ((teer decrease) OR (nn decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 0.61s Refine Results
  1. 6621
  2. 6622

    Shock-Tube Study of the Ignition of Gas-Phase 1,3,5-Trimethylbenzene in Air by Fan Rao (1343973)

    Published 2015
    “…Lean mixtures are fastest to ignite at temperatures above 1390 K at 1.0 atm, whereas they are slowest to ignite below 1300 K at 20.0 atm, and the equivalence ratio does not have an evident effect on the ignition time at 5.0 atm. The global activation energy decreases dramatically as the pressure increases at all equivalence ratios. …”
  3. 6623

    Expression and autolysis of CAPN3 in quadriceps muscle of LGMD2A patients. by Mats I. Nilsson (606586)

    Published 2014
    “…Logically, a reduction in total CAPN3, obtained from Ca<sup>2+</sup>-free homogenates, equates to a decrease in <i>total autolytic capacity</i>. …”
  4. 6624
  5. 6625
  6. 6626
  7. 6627
  8. 6628

    Transient expression of HIF1α(PP) inhibited intracranial tumor growth. by Hyunsung Choi (727224)

    Published 2015
    “…Tumor volumes, plotted in a log scale, decreased significantly from HIF1α(PP) in reference to β-gal. …”
  9. 6629
  10. 6630
  11. 6631

    The association of diabetic retinopathy with metabolic syndrome. by Lu Gao (44114)

    Published 2016
    “…When patients were grouped according to the number of detected components of the metabolic syndrome, the percentage of patients with DR increased linearly with the increasing number of components in their respective groups (14.3%, 38.9%, 49.1%, 61.4%, 83.3%, respectively), whereas, the percentage of patients without DR decreased with the increasing number of components (85.7%, 61.1%, 50.9%, 38.6%, 16.7%, respectively) (Pearson χ<sup>2</sup> = 9.938, P = 0.037). …”
  12. 6632
  13. 6633
  14. 6634
  15. 6635
  16. 6636

    Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators by Lucas B. Fallot (14106171)

    Published 2022
    “…Although having low Caco-2 permeability and high plasma protein binding, hydrophobic 2-cyclohept-4-enyl-<i>N</i>-3,4-dichlorophenyl, MRS7788 <b>18</b>, and 2-heptan-4-yl-<i>N</i>-4-iodophenyl, MRS8054 <b>39</b>, derivatives were orally bioavailable in rat. 2-Heptan-4-yl-<i>N</i>-3,4-dichlorophenyl <b>14</b> and 2-cyclononyl-<i>N</i>-3,4-dichlorophenyl <b>20</b> derivatives and <b>39</b> greatly enhanced Cl-IB-MECA-stimulated [<sup>35</sup>S]GTPγS binding <i>E</i><sub>max</sub>, with only <b>12b</b> trending toward decreasing the agonist EC<sub>50</sub>. A feasible route for radio-iodination at the <i>p-</i>position of a 4-phenylamino substituent suggests a potential radioligand for allosteric site binding. …”
  17. 6637

    Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators by Lucas B. Fallot (14106171)

    Published 2022
    “…Although having low Caco-2 permeability and high plasma protein binding, hydrophobic 2-cyclohept-4-enyl-<i>N</i>-3,4-dichlorophenyl, MRS7788 <b>18</b>, and 2-heptan-4-yl-<i>N</i>-4-iodophenyl, MRS8054 <b>39</b>, derivatives were orally bioavailable in rat. 2-Heptan-4-yl-<i>N</i>-3,4-dichlorophenyl <b>14</b> and 2-cyclononyl-<i>N</i>-3,4-dichlorophenyl <b>20</b> derivatives and <b>39</b> greatly enhanced Cl-IB-MECA-stimulated [<sup>35</sup>S]GTPγS binding <i>E</i><sub>max</sub>, with only <b>12b</b> trending toward decreasing the agonist EC<sub>50</sub>. A feasible route for radio-iodination at the <i>p-</i>position of a 4-phenylamino substituent suggests a potential radioligand for allosteric site binding. …”
  18. 6638
  19. 6639
  20. 6640

    Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth fact... by Bei Cao (141848)

    Published 2023
    “…Coadministration of itraconazole increased the AUC<sub>0-inf</sub> of limertinib by 289.8% (GLSM ratio, 389.8%; 90% CI, 334.07–454.82), but decreased that of CCB4580030 by 35.96% (GLSM ratio, 64.04%; 90% CI, 50.78–80.77).…”